TCM Biotech International Corp. is specialized in the discovery, development and commercialization of botanical drugs derived from the traditional Chinese medicinal ingredient, Cordyceps mycelium, for the treatment of immune and liver diseases.   Dr. Ya-Chun Wang, TCM Biotech¡¦s executive vice president and chief scientific officer, was invited to give a speech on the subject of " the effects of adding a Chinese formulation (TCM-700C) on the standard combination treatment for patients with Genotype 1 hepatitis C infection" in the conference of Fighting Against Hepatitis C From Bench To Practice. [More..]           HCV treatment adjuvant therapy TCM-700C was approved for Phase II clinical trials in Taiwan by both the US Food and Drug Administration (FDA) and Taiwan's Department of Health (DOH). TCM enrolled patients for this clinical trial beginning early 2007.   [More..]           We are specified in screening and isolating technology for natural & precious fungus, which has been recorded in ancient herbal books for medical usage. With serious scientific research, such as toxicity and stability tests, we can ensure to provide the right strains with stable quality and significant effects to the customers by a proprietary fermentation technology.   [More..]
Copyright © 2007 TCM Biotech International Corp. All rights reserved. (The statements on this website have not been evaluated by the US FDA (US Food and Drug Administration). The products are not intended to diagnose, treat, cure or prevent disease.)